Basket Updated
0
Items added
Choosing the best ELISA kit for your research is important. Decide if the FastScan, PathScan, or PathScan RP ELISA kit is right for you.
Do ChIP-validated antibodies work in CUT&RUN assays? Not necessarily. We found only 50-60% of ChIP- or ChIP-seq antibodies were compatible with CUT&RUN.
You may have seen a validation claim from your reagent supplier, but how can you be certain that your antibody is specific?
A multiple-antibody strategy is a powerful approach to antibody validation. The most common method to achieve this is to immunoprecipitate (IP) the target with one antibody and subsequently detect it by western blotting with another antibody against the
Antibody validation principles at Cell Signaling Technology.
Regrettably, none of our GFP antibodies will recognize ZsGreen and copGFP.
Synopsis of CST scientists' publication in the journal Science Signaling describing phosphorylation patterns associated with non-small cell lung cancer (NSCLC).
These samples represent the non-reduced protein and the denatured protein reduced by DDT. Standard western blotting protocols use denaturing conditions to expose epitopes, therefore the reduced sample more accurately reflects the protein's predicted molecular weight. The non-reduced sample shows the observed molecular weight of the non-denatured, folded protein. The difference in the band size of the reduced and non-reduced samples is due to the secondary structure of the protein affecting the protein's mobility in a gel.
Identification of ALK and ROS1 fusion proteins in non-small cell lung cancer (NSCLC) at Cell Signaling Technology.
Unfortunately, due to the nature of lot production, none of the components within the Senescence β-Galactosidase Staining Kit #9860 are available for individual purchase outside of the kit.
July 2013, CST awarded patents critical to lung cancer therapy. Secures dominant IP position for EML4-ALK in NSCLC that spans from research through diagnosis and therapy.
A list of non-profit organizations and communities who have received support from Cell Signaling Technology
Eliminate non-specific binding and high background with the immunohistochemitry (IHC) troubleshooting guide and positive/negative controls
Graphical overview of the tyrosine kinase group of protein kinases featuring receptor and non-receptor (cytoplasmic) tyrosine kinases.
Non-neuronal cells like microglia and astrocytes play critical roles in maintaining proper neuronal function, development, and disease.
Jan 2013, CST granted patent for PCR Methods for detection of a subset of treatable non-small cell lung cancers.
A kinome diagram showing the human tyrosine kinase group. This group of protein kinases comprises receptor and non-receptor tyrosine kinases.
An orthogonal strategy for antibody validation involves cross-referencing antibody-based results with data obtained using non-antibody-based methods.
Our summary of recent findings published in Nature, which indicate that non-performing antibodies were used in many recent macular degeneration studies.
YAP and TAZ are co-expressed abundantly in every cell line that has been shown to be positive for either protein, and likewise, they are negative/low in the same cell lines (essentially, they appear to be quite "redundant" in their pattern of expression). They also have clear molecular weight differences (78 kDa for YAP versus 55 kDa for TAZ), and so it would be apparent if the antibody was detecting both YAP and TAZ. We have not observed evidence in any cell line of a band at 55 kDa when probing with the Non-phospho (Active) YAP (Ser127) (E6U8Z) Rabbit mAb #29495, leading us to conclude that the antibody is specific to YAP. If you look at other YAP-specific antibodies, you will sometimes see degradation products of YAP that may be mis-interpreted as TAZ. With our YAP/TAZ (D24E4) Rabbit mAb #8418, which detects both proteins (designed using TAZ antigen), you can clearly see both proteins at the expected molecular weights.
CST donates lab equipment to Seeding Labs, a non-profit helping scientists in developing countries. Read the interview with Dr. Lillianfeld to learn more.
CST Scientist Richard Cho shares his perspective on the 2017 Sf meeting, including new research findings about non-neuronal cells in the brain.
The mFc tag is about 25 kDa. This tag makes the protein into an "antibody-like" dimer in non-denatured conditions.
Learn how PTMScan technology facilitates translational discovery, identification of disease drivers, and development of markers and treatments, as exemplified in the study of non-small cell lung cancer (NSCLC).
Cell Signaling Technology, Inc. Announces License in Personalized Cancer Diagnostics.
We recommend a 1 hour incubation at room temperature. We have found that prolonged incubation (>2hrs) and elevated incubation temperatures (>25C) can promote non-specific binding.
We always recommend starting with CST CUT&Tag-validated antibodies because CST scientists perform intensive in-house tests to exclude any antibody that tends to show non-specific tagmentation at open chromatin regions (a unique problem for the CUT&Tag assay). If a CUT&Tag-validated antibody is not available, we recommend starting with a CUT&RUN-validated antibody. Alternatively, you may want to try an antibody validated for ChIP, ChIP-seq, or an immunofluorescence assay. The antibody binding in CUT&Tag takes place in an intact nuclear environment, resembling conditions for antibody binding in immunofluorescence assays. If a non-CUT&Tag-validated antibody is used, it is imperative to confirm that there is no non-specific tagmentation, otherwise your results might not be reliable.
Complementary strategies provide vital information regarding antibody specificity or functionality and can be tailored to the nature of the downstream assay.
The top band in the gel image for our Human ACE2 (18-652) Recombinant Protein (mFc-Tag) #83986 likely represents dimerization due to the mFc tag.
